Paying users zone. Data is hidden behind: .
Get 1-month access to Illumina Inc. for $13.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Beginner level
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Illumina Inc., historical price multiples (quarterly data)
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Illumina Inc.’s P/E ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Illumina Inc.’s P/OP ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Illumina Inc.’s P/S ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Illumina Inc.’s P/BV ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Price to Earnings (P/E)
Illumina Inc., historical P/E calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Net income attributable to Illumina stockholders (in millions) | |||||||||||||||||||||||||||||
| Earnings per share (EPS)2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/E ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||||||
| Allergan PLC | |||||||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||||||
| Biogen Inc. | |||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Zoetis Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Data adjusted for splits and stock dividends.
2 Q2 2020 Calculation
EPS
= (Net income attributable to Illumina stockholdersQ2 2020
+ Net income attributable to Illumina stockholdersQ1 2020
+ Net income attributable to Illumina stockholdersQ4 2019
+ Net income attributable to Illumina stockholdersQ3 2019)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.
4 Q2 2020 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Illumina Inc.’s P/E ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Price to Operating Profit (P/OP)
Illumina Inc., historical P/OP calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Income from operations (in millions) | |||||||||||||||||||||||||||||
| Operating profit per share2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/OP ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||||||
| Allergan PLC | |||||||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||||||
| Biogen Inc. | |||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Zoetis Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Data adjusted for splits and stock dividends.
2 Q2 2020 Calculation
Operating profit per share
= (Income from operationsQ2 2020
+ Income from operationsQ1 2020
+ Income from operationsQ4 2019
+ Income from operationsQ3 2019)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.
4 Q2 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Illumina Inc.’s P/OP ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Price to Sales (P/S)
Illumina Inc., historical P/S calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Revenue (in millions) | |||||||||||||||||||||||||||||
| Sales per share2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/S ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||||||
| Allergan PLC | |||||||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||||||
| Biogen Inc. | |||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Zoetis Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Data adjusted for splits and stock dividends.
2 Q2 2020 Calculation
Sales per share
= (RevenueQ2 2020
+ RevenueQ1 2020
+ RevenueQ4 2019
+ RevenueQ3 2019)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.
4 Q2 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Illumina Inc.’s P/S ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Price to Book Value (P/BV)
Illumina Inc., historical P/BV calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Total Illumina stockholders’ equity (in millions) | |||||||||||||||||||||||||||||
| Book value per share (BVPS)2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/BV ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||||||
| Allergan PLC | |||||||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||||||
| Biogen Inc. | |||||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
| Zoetis Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Data adjusted for splits and stock dividends.
2 Q2 2020 Calculation
BVPS = Total Illumina stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.
4 Q2 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Illumina Inc.’s P/BV ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |